Actively Recruiting
REGistry of Long-term AnTithrombotic TherApy-2
Led by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Updated on 2026-05-01
2000
Participants Needed
1
Research Sites
624 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation
CONDITIONS
Official Title
REGistry of Long-term AnTithrombotic TherApy-2
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Documented atrial fibrillation with CHA2DS2VASC score greater than 1
You will not qualify if you...
- Unable or unwilling to provide informed consent
- Acute coronary syndrome within 12 months before inclusion
- Severe congestive heart failure (NYHA class IV)
- Stroke within 6 months before inclusion
- Severe liver or muscle disease
- Severe kidney disease or renal failure with creatinine greater than 3 mg/dl
- Inability to contact the patient or their family one year after the intervention
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Moscow, Russia, 121552
Actively Recruiting
Research Team
E
Ekaterina Kropacheva, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here